210 related articles for article (PubMed ID: 25297758)
21. A case of follicular lymphoma associated with paraneoplastic cerebellar degeneration.
Shimazu Y; Minakawa EN; Nishikori M; Ihara M; Hashi Y; Matsuyama H; Hishizawa M; Yoshida S; Kitano T; Kondo T; Ishikawa T; Takahashi R; Takaori-Kondo A
Intern Med; 2012; 51(11):1387-92. PubMed ID: 22687848
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in lymphoma without blood product support.
Sefcick A; Byrne JL; Russell NH
Bone Marrow Transplant; 2000 Nov; 26(10):1140-1. PubMed ID: 11108322
[No Abstract] [Full Text] [Related]
23. 6th European Hematology Association Meeting. Frankfurt, Germany. June 21-24, 2001.
Maung K; D'Orazio AI
Clin Lymphoma; 2001 Sep; 2(2):74-9. PubMed ID: 11712544
[No Abstract] [Full Text] [Related]
24. [Standard of care and new drugs for diffuse large B-cell lymphoma].
Yamamoto K
Rinsho Ketsueki; 2014 Oct; 55(10):1920-8. PubMed ID: 25297756
[No Abstract] [Full Text] [Related]
25. Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy.
Al-Salman J; Salib H; Boonswang P
Med Oncol; 2001; 18(4):277-83. PubMed ID: 11918454
[TBL] [Abstract][Full Text] [Related]
26. [Follicular lymphoma].
Tomita N
Nihon Rinsho; 2014 Mar; 72(3):488-92. PubMed ID: 24724409
[TBL] [Abstract][Full Text] [Related]
27. Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma.
Ghielmini M
Cancer Treat Rev; 2005 Dec; 31(8):644-7. PubMed ID: 16289339
[No Abstract] [Full Text] [Related]
28. A case of CD20-positive peripheral T-cell lymphoma treated with rituximab and multiagent chemotherapy.
Kamata M; Sugaya M; Miyagaki T; Sonoda K; Ichimura Y; Mitsui H; Sato S; Kamikubo Y; Kurokawa M
Int J Dermatol; 2014 Jan; 53(1):e24-6. PubMed ID: 23452101
[No Abstract] [Full Text] [Related]
29. Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites.
Hiroshima Y; Tajima K; Shiono Y; Suzuki I; Kouno K; Yamamoto M; Kato Y; Kato T
Ann Hematol; 2012 Sep; 91(9):1499-500. PubMed ID: 22281990
[No Abstract] [Full Text] [Related]
30. [Systemic follicular lymphoma with cutaneous manifestations and exclusively cutaneous recurrence].
Palacios Abufón A; Acebo Mariñas E; Gardeazabal García J; García-Ruiz JC
Actas Dermosifiliogr; 2012 Apr; 103(3):253-5. PubMed ID: 22093542
[No Abstract] [Full Text] [Related]
31. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
[TBL] [Abstract][Full Text] [Related]
32. Novel treatment strategies in follicular lymphoma.
Buske C; Dreyling H; Unterhalt M; Hiddemann W
Ann Hematol; 2004; 83 Suppl 1():S72. PubMed ID: 15124680
[TBL] [Abstract][Full Text] [Related]
33. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.
Hernandez MC; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1274-87. PubMed ID: 15275710
[TBL] [Abstract][Full Text] [Related]
34. [Treatment strategy of Hodgkin lymphoma].
Nagai H
Rinsho Ketsueki; 2014 Oct; 55(10):1941-51. PubMed ID: 25297759
[No Abstract] [Full Text] [Related]
35. [Thyroid malignant lymphoma].
Noh JY; Shimizu T; Ito K
Nihon Rinsho; 2006 May; Suppl 1():482-4. PubMed ID: 16776195
[No Abstract] [Full Text] [Related]
36. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
37. Polymyositis following autologous haematopoietic stem cell transplantation.
Hedermann G; Marquart HV; Vissing J
Scand J Rheumatol; 2016 Oct; 45(5):429-31. PubMed ID: 27050436
[No Abstract] [Full Text] [Related]
38. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
39. Primary gastrointestinal follicular lymphoma with histological transformation.
Hangai S; Nakamura F; Kamikubo Y; Ichikawa M; Suzuki H; Yoshida S; Yamada A; Takazawa Y; Fukayama M; Koike K; Kurokawa M
Ann Hematol; 2013 Jul; 92(7):993-4. PubMed ID: 23271213
[No Abstract] [Full Text] [Related]
40. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
